Predicting Response to Risperidone Treatment Through Identification of Early-Onset of Antipsychotic Drug Action in Schizophrenia.

Trial Profile

Predicting Response to Risperidone Treatment Through Identification of Early-Onset of Antipsychotic Drug Action in Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2010

At a glance

  • Drugs Olanzapine; Risperidone
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Jan 2010 Results reported in Neuropsychopharmacology.
    • 01 Jan 2010 Secondary endpoint 'Montgomery Asberg Depression Rating Scale' has been met.
    • 01 Jan 2010 Primary endpoint 'Positive and Negative Syndrome Scale' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top